trial

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

NCTId NCT02758067
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Withdrawn
Enrollment 0 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2016-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-06
Primary completion
2016-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)Risperidone

Sponsors

H. Lundbeck A/SLead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Collaborator

Sites

0 total

Linked catalysts

1
Comparison of the Effectiveness of Brexpiprazole With That of Risperidone — primary completion2016-06

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE3
Primary Completion Date
2016-06
Status
WITHDRAWN
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
Risperidone
drug
lead_sponsor
H. Lundbeck A/S
company
collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication